Colombia at the centre of preclinical AD research
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The age of symptomatic onset in asymptomatic FAD subjects with presenilin 1 mutations is reasonably predictable.
“An alternative design will test Aβ-based interventions in asymptomatic FAD subjects with presenilin 1 mutations, as their age of symptomatic onset is reasonably predictable [259, 260].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [260]
Cited by
Sorted by citations
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · see citing works
Nicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A. M., Harris, S., Love, S., Neal, J., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 205 · see citing works
Passive immunotherapy for Alzheimer's disease: What have we learned, and where are we headed?
Aisen, P. S. S., & Vellas, B. J. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0001-3 · Cited by 23 · see citing works
“Crenezumab has been selected for the coming trial in familial autosomal dominant ad conducted by the alzheimer’s Prevention initiative group (9).”
Yan, C., Wang, Y., Ma, Y., Liu, H., Tang, S., Li, Y., Shi, J., Ding, S., & Lyu, Z. (2024) · Materials Today Chemistry · doi:10.1016/j.mtchem.2024.102222 · Cited by 17 · see citing works
Potential sources of interference on Abeta immunoassays in biological samples
Vanderstichele, H., Stoops, E., Vanmechelen, E., & Jeromin, A. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt142 · Cited by 15 · see citing works
Women with the Alzheimer’s risk marker ApoE4 lose Aβ-specific CD4+ T cells 10–20 years before men
Begum, A. N., Cunha, C. D., Sidhu, H., Alkam, T., Scolnick, J., Rosario, E. R., & Ethell, D. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.51 · Cited by 15 · see citing works
Cardona‐Gómez, G. P., & Lopera, F. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00304 · Cited by 11 · see citing works
“…first prevention trial of crenezumab immunotherapy developed by Genentech, Banner and our research group ‘‘GNle of A’’, is being evaluated with high risk members from families carrying the E280A-PS1 AD mutation, before onset of mild cognitive impairment (MCI) stage (Neurology, 2012).”
BackgroundRavenscroft, T. A., Pottier, C. P., Murray, M. E., Baker, M. C., Christopher, E. A., Levitch, D., Brown, P. H., Barker, W., Duara, R., Greig‐Custo, M. T., et al. (2016) · Europe PMC (PubMed Central) · Cited by 8 · see citing works
Primary or secondary prevention for AD: who cares?
Frisoni, G. B., & Trojanowski, J. Q. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70143-6 · Cited by 2 · see citing works
Flavonoids in Transgenic Alzheimer's Disease Mouse Models
Sabogal-Guáqueta, A. M., Osorio, E., & Cardona-Gómez, G. P. (2017) · doi:10.1002/9781119155195.ch2 · Cited by 2 · see citing works
Present and Future Therapies for Alzheimer’s Disease
Nagase, H., & Nakayama, K. (2018) · InTech eBooks · doi:10.5772/intechopen.75449
- Authors
- Neurology, T. L.
- Corresponding author
- The Lancet Neurology
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 11
- Issue
- 7
- Pages
- 567
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4243138748
- Cited by
- 11
- References
- 0
- Citations by year
- 2024: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2014: 1 · 2013: 2 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid hypothesis, anti-amyloid therapy, crenezumab, early-onset familial Alzheimer's disease, primary prevention trials, NIH funding
- MeSH terms
- Alzheimer Disease, Antibodies, Monoclonal, Clinical Trials as Topic, Colombia, Humans, Biomedical Research, Presenilins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
